Association of calcitriol supplementation with reduced COVID-19 mortality in patients with chronic kidney disease: a population-based study

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Oristrell, Joaquim
• dc.contributor.author Oliva, Joan Carles
• dc.contributor.author Subirana Cachinero, Isaac
• dc.contributor.author Casado, Enrique
• dc.contributor.author Domínguez, Didier
• dc.contributor.author Toloba, Andrea
• dc.contributor.author Aguilera, Patricia
• dc.contributor.author Esplugues, Joan
• dc.contributor.author Fafián, Pilar
• dc.contributor.author Grau Magaña, Maria
• dc.date.accessioned 2021-09-01T06:46:57Z
• dc.date.available 2021-09-01T06:46:57Z
• dc.date.issued 2021
• dc.description.abstract Treatment with calcitriol, the hormonal form of vitamin D, has shown beneficial effects in experimental models of acute lung injury. In this study, we aimed to analyze the associations between calcitriol supplementation and the risk of SARS-CoV2 infection or COVID-19 mortality. Individuals ≥18 years old living in Catalonia and supplemented with calcitriol from April 2019 to February 2020 were compared with propensity score matched controls. Outcome variables were SARS-CoV2 infection, severe COVID-19 and COVID-19 mortality. Associations between calcitriol supplementation and outcome variables were analyzed using multivariable Cox proportional regression. A total of 8076 patients were identified as being on calcitriol treatment. Advanced chronic kidney disease and hypoparathyroidism were the most frequent reasons for calcitriol supplementation in our population. Calcitriol use was associated with reduced risk of SARS-CoV2 infection (HR 0.78 [CI 95% 0.64-0.94], p = 0.010), reduced risk of severe COVID-19 and reduced COVID-19 mortality (HR 0.57 (CI 95% 0.41-0.80), p = 0.001) in patients with advanced chronic kidney disease. In addition, an inverse association between mean daily calcitriol dose and COVID-19 severity or mortality was observed in treated patients, independently of renal function. Our findings point out that patients with advanced chronic kidney disease could benefit from calcitriol supplementation during the COVID-19 pandemic.
• dc.format.mimetype application/pdf
• dc.identifier.citation Oristrell J, Oliva JC, Subirana I, Casado E, Domínguez D, Toloba A, Aguilera P, Esplugues J, Fafián P, Grau M. Association of calcitriol supplementation with reduced COVID-19 mortality in patients with chronic kidney disease: a population-based study. Biomedicines. 2021;9(5):509. DOI: 10.3390/biomedicines9050509
• dc.identifier.doi http://dx.doi.org/10.3390/biomedicines9050509
• dc.identifier.issn 2227-9059
• dc.identifier.uri http://hdl.handle.net/10230/48356
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Biomedicines. 2021;9(5):509
• dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword COVID-19
• dc.subject.keyword SARS-CoV2 infection
• dc.subject.keyword Calcitriol
• dc.subject.keyword Chronic kidney disease
• dc.subject.keyword Vitamin D
• dc.title Association of calcitriol supplementation with reduced COVID-19 mortality in patients with chronic kidney disease: a population-based study
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion